How would you manage a patient with Stage IVB DLBCL with refractory disease in the retroperitoneum and spleen after 6 cycles of RCHOP?
Would you offer refractory doses (40-50 Gy) to the RPnodes and send for splenectomy? Or would you offer refractory doses to both RP nodes and spleen?
Answer from: Radiation Oncologist at Academic Institution
The management of primary refractory stage IV DLBCL is complex and generally not successful. See NCCN Guidelines for details. I would distinguish, however, between those patients who are clinically refractory and those who have clinically responded well but may have residual disease by imaging, i.e....
Comments
Medical Oncologist at St Louis Cancer Care LLP I also wonder when and if bispecific antibodies wi...
Medical Oncologist at Valley Med Onc CAR-T cell therapy.
Answer from: Medical Oncologist at Academic Institution
It is hard to give specific recommendations without more information about the patient and the specific clinical scenario. But general guiding principles: 1) ensure that the disease is indeed primary refractory, with a diagnostically adequate biopsy confirming refractory viable lymphoma. 2) If patie...
Comments
Radiation Oncologist at Munson Medical Center @Matthew J. Matasar, @Craig R. Hildreth, @Byron E....
Radiation Oncologist at Delaware Valley Urology Cancer Treatment Center A patient who failed at least one line of a standa...
Medical Oncologist at Rutgers Cancer Institute of New Jersey Dr. @Carol L. Kornmehl - clearly a challengin...
Radiation Oncologist at Delaware Valley Urology Cancer Treatment Center Agreed. Thank you so much.
Answer from: Medical Oncologist at Community Practice
Certainly obtaining a biopsy for confirmation of refractory disease is prudent! I would certainly work towards getting approval for CAR-T; current FDA label would require that the patient has failed 2 lines of therapies so, in such patient, I would give no more than 1-2 cycles of salvage chemotherap...
I also wonder when and if bispecific antibodies wi...
CAR-T cell therapy.